GSK LATAM
在场
GSK LATAM 的所有者是 GSK.
是其中之一......
- Forbes Global 2000 (#183);
- Fortune 500 Europe (#104);
- FTSE 350;
- Global Fortune 500 (#400);
- Stoxx 600;
- TOB Iconic 10,000.
GSK 是一家在股票代码 GSK (GB) 下上市的公司。
GSK 在 21 个国家有直接业务。GSK 拥有 24家子公司，其中包括 Aiolos Bio、GSK ANZ 和 GSK APAC。
他们在：
涉及GSK的并购和融资。
- GSK has announced the acquisition of Aiolos Bio (公布2024一月12号).
- GSK has announced the acquisition of Bellus Health (公布2023四月19号).
高管
查看带有其 2 名主要高管的组织结构图
GSK LATAM 搜索最多的简介
高管在GSK变化
- Jeannie LeeJeannie Lee 将于20243月3作为 Non-Executive Director 加入公司 (新闻发布的2024二月29号).
创建提醒
跟踪 GSK LATAM 的高管变动
药店
GSK 拥有 1,837 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Grace Therapeutics将在Oct 24, 2024将其名称改为Grace Therapeutics。 (公布2024十月27号).
- Orasis Pharmaceuticals 刚刚宣布为 78 筹款数百万美元。 (公布2024十月21号).
- Lundbeck has announced the acquisition of Longboard Pharmaceuticals (公布2024十月17号).
药店 行业的其他推荐联系人
消息
GSK LATAM 的最新新闻稿
- GSK on track to deliver 2024 outlooks with further good progress made in R&D | GSK
- GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline | GSK
- GSK and Cambridge University announce new five-year collaboration in kidney and respiratory disease | GSK
- New data for Arexvy, GSK’s respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease | GSK
- ViiV Healthcare shows more than 99% effectiveness in real-world studies for Apretude (cabotegravir long-acting), the only approved long-acting HIV PrEP, in data presented at IDWeek 2024 | GSK
- Gepotidacin accepted for priority review by US FDA for treatment of uncomplicated urinary tract infections in female adults and adolescents | GSK
- Statement: Zantac (ranitidine) litigation – settlement agreements reached | GSK
- GSK and ViiV Healthcare to showcase advances across industry-leading infectious disease portfolio at IDWeek 2024 | GSK
- GSK announces positive phase III results from ANCHOR trials for depemokimab in chronic rhinosinusitis with nasal polyps | GSK
- GSK presents positive data for Arexvy, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons | GSK
- View more press releases Close
